Condition
Islets of Langerhans Transplantation
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownEfficacy of Islet Re-transplantation After Failure of Beta-cell ReplacementNCT07666789 · 2025-07-31
RECRUITINGArginine-stimulated Indication of Early Outcome After Islet TransplantationNCT05540197 · 2023-02-23
UNKNOWNClinical Outcome After Total Pancreatectomy With Islet AutotransplantationNCT05287737 · 2022-06-21
ENROLLING_BY_INVITATIONNovel Method of Pancreatic Islet Transplantation Into the OmentumNCT04884633 · 2019-08-15
UNKNOWNIslet Transplant Alone in OMENtumNCT02803905 · 2016-04-01
UNKNOWNCalcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic PatientsNCT01033500 · 2010-07-01
WITHDRAWNCadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes MellitusNCT00579371 · 2004-03-17
TERMINATEDhOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft FailureNCT00008801
UNKNOWNCommon interventions
Leading sponsors
Trial status mix
UNKNOWN4
ENROLLING_BY_INVITATION1
RECRUITING1
TERMINATED1
WITHDRAWN1
Phase mix
PHASE23
NA2
PHASE12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.